Categories: Rare diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Hemophilia

MalaCards integrated aliases for Hemophilia:

Name: Hemophilia 72 50 25 29 41 3
Hemophilia, Hereditary 25
Hemophilia, Familial 25
Hemophilia, Nos 69
Hemophilia a 69


Summaries for Hemophilia

NIH Rare Diseases : 50 hemophilia is a bleeding disorder that slows the blood clotting process. people with this disorder experience prolonged bleeding following an injury, surgery, or having a tooth pulled. in severe cases, heavy bleeding occurs after minor trauma or in the absence of injury. serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. the major types of this disorder are hemophilia a and hemophilia b. although the two types have very similar signs and symptoms, they are caused by mutations in different genes. people with an unusual form of hemophilia b, known as hemophilia b leyden, experience episodes of excessive bleeding in childhood, but have few bleeding problems after puberty. another form of the disorder, acquired hemophilia, is not caused by inherited gene mutations. last updated: 1/10/2012

MalaCards based summary : Hemophilia, also known as hemophilia, hereditary, is related to mild hemophilia b and moderately severe hemophilia b, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Hemophilia is F8 (Coagulation Factor VIII), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Bevacizumab and Thrombin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cardiovascular system

MedlinePlus : 41 hemophilia is a rare disorder in which the blood does not clot normally. it is usually inherited. hemophilia usually occurs in males. if you have hemophilia, you have little or no clotting factor. clotting factor is a protein needed for normal blood clotting. without it, you may bleed for a long time after an injury or accident. you also may bleed into your knees, ankles, and elbows. bleeding in the joints causes pain and, if not treated, can lead to arthritis. bleeding in the brain, a very serious complication of hemophilia, requires emergency treatment. the main symptoms of hemophilia are excessive bleeding and easy bruising. blood tests can tell if you have it. the main treatment is injecting the missing clotting factor into the bloodstream. you may need it on a regular basis, or just when bleeding occurs. nih: national heart, lung, and blood institute

CDC : 3 Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. People with hemophilia can live full lives and enjoy most of the activities that other people do. If you have hemophilia, or know someone who does, it’s important to learn how to stay as healthy as possible.

Genetics Home Reference : 25 Hemophilia is a bleeding disorder that slows the blood clotting process. People with this condition experience prolonged bleeding or oozing following an injury, surgery, or having a tooth pulled. In severe cases of hemophilia, continuous bleeding occurs after minor trauma or even in the absence of injury (spontaneous bleeding). Serious complications can result from bleeding into the joints, muscles, brain, or other internal organs. Milder forms of hemophilia do not necessarily involve spontaneous bleeding, and the condition may not become apparent until abnormal bleeding occurs following surgery or a serious injury.

Related Diseases for Hemophilia

Diseases in the Hemophilia family:

Hemophilia B Hemophilia a
Acquired Hemophilia Acquired Hemophilia a
Severe Hemophilia a Severe Hemophilia B

Diseases related to Hemophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
id Related Disease Score Top Affiliating Genes
1 mild hemophilia b 33.3 F8 VWF
2 moderately severe hemophilia b 31.7 F2 F3 F8 LOC106146150 LOC106146152
3 von willebrand disease, type 1 30.9 F7 VWF
4 von willibrand disease, type 3 30.3 F2 F3 F8 VWF
5 hemolytic-uremic syndrome 29.1 F2 F3
6 femoral neuropathy 29.0 F3 F8 VWF
7 ischemic heart disease 28.9 F2 VWF
8 peripheral artery disease 28.6 F2 F3 VWF
9 myeloproliferative neoplasm 28.3 F2 F3 F8 VWF
10 factor v deficiency 27.7 F2 F3 F7 F8 F9
11 factor x deficiency 27.5 F2 F3 F7 F8 F9
12 myocardial infarction 27.4 F2 F3 F7 F8 VWF
13 essential thrombocythemia 26.5 F2 F3 F7 F8 F9 VWF
14 hemophilia b 12.5
15 hemophilia a 12.4
16 acquired hemophilia 12.2
17 acquired hemophilia a 12.1
18 severe hemophilia a 11.9
19 severe hemophilia b 11.9
20 mild hemophilia a 11.9
21 moderately severe hemophilia a 11.8
22 symptomatic form of hemophilia a in female carriers 11.7
23 symptomatic form of hemophilia b in female carriers 11.7
24 hemarthrosis 11.1
25 von willebrand's disease 11.1
26 thrombosis 11.1
27 thrombophilia 11.1
28 factor xi deficiency, autosomal recessive 11.1
29 factor v and factor viii, combined deficiency of 10.9
30 combined factor v and viii deficiency 10.9
31 von willebrand disease, types 2a, 2b, 2m, and 2n 10.7
32 intermediate anorectal malformation 10.7 F8 F9
33 multiple congenital anomalies mental retardation, growth failure and cleft lip palate 10.5 F3 F8
34 angioedema, hereditary, type iii 10.4 F3 F9
35 social phobia 10.4 F2 F8
36 rheumatoid lung disease 10.4 F2 F8
37 intestinal pseudo-obstruction 10.4 F2 F8
38 ubqln2-related amyotrophic lateral sclerosis/frontotemporal dementia 10.4 F8 VWF
39 uchl1-related parkinson disease susceptibility 10.4 F8 VWF
40 neuroaxonal dystrophy 10.4 F2 F8
41 floppy infant syndrome 10.4 F8 VWF
42 ube2t-related fanconi anemia 10.4 F8 VWF
43 rete ovarii adenoma 10.4 F2 F8
44 hyperthyroidism 10.3 F2 F3
45 pyridoxine deficiency anemia 10.3 F2 F3
46 46,xy ovotesticular disorder of sex development 10.3 F2 F3
47 myiasis 10.3 F2 F3
48 testicular gonadoblastoma 10.3 F2 F3
49 rectum neuroendocrine neoplasm 10.3 F2 F3
50 midline cystocele 10.3 F2 F3

Comorbidity relations with Hemophilia via Phenotypic Disease Network (PDN):

Deficiency Anemia

Graphical network of the top 20 diseases related to Hemophilia:

Diseases related to Hemophilia

Symptoms & Phenotypes for Hemophilia

UMLS symptoms related to Hemophilia:

angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Hemophilia according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.68 TFPI
2 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.68 TFPI
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.68 F2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.68 F2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.68 F2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.68 F2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.68 F9
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.68 F2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.68 F9
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.68 TFPI
11 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.68 F2 F9 TFPI
12 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.68 TFPI
13 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.68 F9
14 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.68 TFPI
15 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.68 F9
16 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.68 F9
17 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.68 F2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-44 9.68 F9
19 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.68 TFPI
20 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.68 F9
21 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.68 F9

MGI Mouse Phenotypes related to Hemophilia:

id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.1 F3 F7 F9 TFPI VWF F2

Drugs & Therapeutics for Hemophilia

Drugs for Hemophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Bevacizumab Approved, Investigational Phase 4 216974-75-3
Thrombin Approved Phase 4,Phase 2,Phase 3
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
Menthol Approved Phase 4,Early Phase 1 2216-51-5 16666
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
Indinavir Approved Phase 4,Phase 3,Phase 2 150378-17-9 5362440
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2 3056-17-5 18283
Zalcitabine Approved Phase 4,Phase 3,Phase 2 7481-89-2 24066
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2 198153-51-4 5360545
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
Fluconazole Approved Phase 4 86386-73-4 3365
20 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
21 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Factor VIII Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Angiogenesis Inhibitors Phase 4
24 Angiogenesis Modulating Agents Phase 4
25 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1
26 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
29 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Antifungal Agents Phase 4,Phase 3
32 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
33 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
Histamine Phosphate Phase 4 51-74-1 65513
36 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Antifibrinolytic Agents Phase 4
41 Adjuvants, Immunologic Phase 4
42 Hylan Phase 4
43 Protective Agents Phase 4
44 triamcinolone acetonide Phase 4
45 Triamcinolone diacetate Phase 4
46 Triamcinolone hexacetonide Phase 4
47 Viscosupplements Phase 4
48 Interferon-alpha Phase 4,Phase 2
49 interferons Phase 4,Phase 3,Phase 2
50 Complement Factor I Phase 4

Interventional clinical trials:

(show top 50) (show all 555)

id Name Status NCT ID Phase Drugs
1 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
2 Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Unknown status NCT02060305 Phase 4 Bevacizumab intra-articular injection
3 Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery Completed NCT00092976 Phase 4 ReFacto
4 Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII Completed NCT00284193 Phase 4 rFVIIa-FEIBA therapy for hemophilia A inhibitors;FEIBA- Activated Prothrombin Complexes
5 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
6 Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use Completed NCT00167973 Phase 4
7 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Completed NCT00357656 Phase 4 Recombinant Protein-Free Factor VIII (rAHF-PFM);Recombinant Protein-Free Factor VIII (rAHF-PFM)
8 Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B Completed NCT00581126 Phase 4 Recombinant Factor IX Coagulation
9 Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients Completed NCT02727647 Phase 4 FVIII;FVIII
10 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
11 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
12 Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B Completed NCT00195221 Phase 4
13 Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) Completed NCT00139828 Phase 4 human coagulation Factor IX
14 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
15 Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A Completed NCT00168051 Phase 4 ReFacto;Advante
16 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
17 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A Completed NCT02492984 Phase 4 Intravenous infusions of Xyntha
18 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
19 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A Completed NCT00666406 Phase 4 Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM);Recombinant Factor VIII (rAHF)
20 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A Completed NCT00916032 Phase 4
21 Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients Completed NCT00244114 Phase 4 blood draw
22 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00243386 Phase 4 Antihemophilic factor, recombinant, manufactured protein-free;Antihemophilic factor, recombinant, manufactured protein-free
23 Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia Completed NCT00002386 Phase 4 Indinavir sulfate;Lamivudine;Stavudine;Zidovudine;Zalcitabine;Didanosine
24 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
25 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00289536 Phase 4
26 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
27 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
28 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting Completed NCT00950170 Phase 4
29 IMMUNINE Pre-Treatment Study Completed NCT01128881 Phase 4
30 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
31 A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor Completed NCT01800435 Phase 4 aPCC, aPCC + TXA;rFVIIa, rFVIIa + TXA
32 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
33 Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX Completed NCT00749476 Phase 4
34 China ADVATE PTP Study Completed NCT02170402 Phase 4
35 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy Completed NCT00638001 Phase 4
36 Survey of Inhibitors in Plasma-Product Exposed Toddlers Completed NCT01064284 Phase 4 PLASMA DERIVED Factor VIII;Recombinant FVIII
37 Viscosupplementation in Patients With Hemophilic Arthropathy Completed NCT01748201 Phase 4
38 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. Completed NCT00475072 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin
39 Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection Completed NCT00707772 Phase 4 PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin);PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
40 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
41 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
42 Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion Completed NCT01955811 Phase 4 Administration of platelet concentrate and taking blood samples
43 Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease Completed NCT00364858 Phase 4 Cerezyme
44 A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Completed NCT00000951 Phase 4 Fluconazole
45 Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A Recruiting NCT00323856 Phase 4 Alphanate SD/HT
46 Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients Recruiting NCT02479087 Phase 4 Plasma-derived FVIII/VWF concentrate
47 Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies Recruiting NCT03103542 Phase 4
48 A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Recruiting NCT02999308 Phase 4
49 A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study) Recruiting NCT03093480 Phase 4
50 DDAVP vs. Exercise Recruiting NCT03136003 Phase 4 DDAVP intervention

Search NIH Clinical Center for Hemophilia

Inferred drug relations via UMLS 69 / NDF-RT 48 :

Genetic Tests for Hemophilia

Genetic tests related to Hemophilia:

id Genetic test Affiliating Genes
1 Hemophilia 29

Anatomical Context for Hemophilia

MalaCards organs/tissues related to Hemophilia:

Brain, Testes, Liver, Lung, Heart, Bone, T Cells

Publications for Hemophilia

Articles related to Hemophilia:

(show top 50) (show all 1889)
id Title Authors Year
Mortality caused by intracranial bleeding in non-severe hemophilia A patients. ( 28374963 )
A retrospective study of cytokine profiles changes in mice with FVIII inhibitor development after AAV mediated gene therapy in hemophilia A mouse model. ( 28922951 )
Acquired Hemophilia A After Hepatic Yttrium-90 Radioembolization: A Case Report. ( 28767473 )
Revascularization strategies and in-hospital management in acute coronary syndromes complicated by hemophilia A or hemophilia B. ( 28763308 )
Perioperative Coagulation Management of a Hemophilia A Patient During Cardiac Surgery. ( 28388863 )
Acquired hemophilia as initial presentation in a patient with Systemic Lupus Erythematosus. ( 28523993 )
Chromogenic Factor VIII Assays for Improved Diagnosis of Hemophilia A. ( 28804835 )
Mortality caused by intracranial bleeding in non-severe hemophilia A patients: comment. ( 28600843 )
Acquired hemophilia A: Updated review of evidence and treatment guidance. ( 28470674 )
The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program. ( 28079788 )
The State of Skewed X Chromosome Inactivation is Retained in the Induced Pluripotent Stem Cells from a Female with Hemophilia B. ( 28401797 )
Treatment and complications in acquired hemophilia A. Experience from a single center. ( 28919213 )
Gene Therapy for Hemophilia. ( 28895852 )
Screening of Intron 1 Inversion of the Factor VIII Gene in 130 Patients with Severe Hemophilia A from a Pakistani Cohort. ( 28294101 )
Usual and unusual mutations in a cohort of Belgian patients with hemophilia B. ( 27865967 )
Blood feud erupts over Roche's bispecific antibody for hemophilia. ( 28898214 )
Minimally Invasive Aortic Valve Replacement in a Patient With Severe Hemophilia A. ( 28153454 )
Driving the hemophilia tolerance CAR. ( 28082293 )
Understanding adherence to treatment and physical activity in children with hemophilia: The role of psychosocial factors. ( 28067581 )
Mortality caused by intracranial bleeding in non-severe hemophilia A patients: reply. ( 28618141 )
Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study. ( 28326849 )
Biodistribution of Liver-Derived Mesenchymal Stem Cells After Peripheral Injection in a Hemophilia A Patient. ( 28738402 )
First case report of hemophilia B Leyden in Japan. ( 28168417 )
Acquired hemophilia A manifesting as plasma transfusion-uncontrolled severe bleeding 2 weeks after chorioamnionitis-induced abortion. ( 28150393 )
Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon. ( 28457068 )
Identification of patients with congenital hemophilia in a large electronic health record database. ( 28919830 )
Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene. ( 28905885 )
Hemophilia Management via Data Collection and Reporting: Initial Findings from the Comprehensive Care Sustainability Collaborative. ( 28025929 )
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-NaA^ve or Treatment-Experienced. ( 28874040 )
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action. ( 28932824 )
Acquired hemophilia A following generalized pustular psoriasis of pregnancy. ( 28771773 )
First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin. ( 28597369 )
Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated. ( 28799202 )
Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. ( 28860720 )
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
Hemophilic pseudotumor of the mandible in a patient with hemophilia B. ( 28852852 )
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. ( 28944952 )
Emerging Therapeutic Strategies in the Treatment of Hemophilia A. ( 28750425 )
Acute Compartment Syndrome after an Olecranon Fracture in a Patient with Mild Hemophilia B. ( 28819614 )
Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. ( 28166608 )
A Case of Hemophilia A Presenting in a Neonate and a Review of the Literature. ( 28321438 )
Diagnosis and treatment of congenital and acquired hemophilia. ( 28781285 )
Successful Management of Acquired Hemophilia A Associated with Bullous Pemphigoid: A Case Report and Review of the Literature. ( 28458935 )
Initial Manifestation of Acquired Hemophilia A After a Routine Tooth Extraction. A Case Report and Literature Review. ( 28886353 )
Single-tube tetradecaplex panel of highly polymorphic microsatellite markers < 1 Mb from F8 for simplified preimplantation genetic diagnosis of hemophilia A. ( 28345288 )
Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study. ( 28319338 )
An extra X does not prevent acquired hemophilia - Pregnancy-associated acquired hemophilia A. ( 28262242 )
CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice. ( 28508290 )
Novel Mutations Resulting in a Moderate to Severe Phenotypic Manifestation of Hemophilia A in a Female. ( 28452855 )
Evaluating the psychosocial impact of hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study. ( 28319335 )

Variations for Hemophilia

Expression for Hemophilia

Search GEO for disease gene expression data for Hemophilia.

Pathways for Hemophilia

Pathways related to Hemophilia according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
Show member pathways
12.94 F2 F3 F7 F8 F9 TFPI
Show member pathways
12.35 F2 F3 F7 F8 F9 TFPI
Show member pathways
11.71 F2 F3 F7 F8 F9 TFPI
Show member pathways
11.58 F2 F7 F9
5 11.31 F2 F3 F7 F8 F9 TFPI
6 11.14 F2 VWF
7 10.9 F2 TFPI
8 10.61 F2 F7 F9

GO Terms for Hemophilia

Cellular components related to Hemophilia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 F2 F3 F7 F8 F9 TFPI
2 extracellular region GO:0005576 9.7 F2 F3 F7 F8 F9 TFPI
3 Golgi lumen GO:0005796 9.43 F2 F7 F9
4 endoplasmic reticulum lumen GO:0005788 9.26 F2 F7 F8 F9
5 serine-type peptidase complex GO:1905286 8.62 F3 F7

Biological processes related to Hemophilia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.71 F2 F7 F8 F9
2 platelet activation GO:0030168 9.65 F2 F8 VWF
3 blood coagulation, intrinsic pathway GO:0007597 9.56 F2 F8 F9 VWF
4 signal peptide processing GO:0006465 9.54 F2 F7 F9
5 protein processing GO:0016485 9.52 F3 F7
6 acute-phase response GO:0006953 9.51 F2 F8
7 peptidyl-glutamic acid carboxylation GO:0017187 9.5 F2 F7 F9
8 blood coagulation GO:0007596 9.5 F2 F3 F7 F8 F9 TFPI
9 positive regulation of blood coagulation GO:0030194 9.49 F2 F7
10 positive regulation of positive chemotaxis GO:0050927 9.46 F3 F7
11 blood coagulation, extrinsic pathway GO:0007598 9.46 F3 F7 F9 TFPI
12 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.43 F3 F7
13 hemostasis GO:0007599 9.17 F2 F3 F7 F8 F9 TFPI

Molecular functions related to Hemophilia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serine-type peptidase activity GO:0008236 9.13 F2 F7 F9
2 serine-type endopeptidase activity GO:0004252 8.92 F2 F3 F7 F9

Sources for Hemophilia

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....